-
Mashup Score: 0Cancer’s New Face: Younger and Female - 2 hour(s) ago
Although long considered a disease of aging, certain cancers are turning up more often in younger women, according to a new report.
Source: www.nytimes.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1December 2024 OSUCCC – James Grants, Awards and Honors - 2 hour(s) ago
The OSUCCC – James announces the following awards, honors, grants and more that were recently given to the organization, teams or individuals.
Source: cancer.osu.eduCategories: General Medicine News, Hem/OncsTweet-
Another month, another round of amazing accomplishments by the @OSUCCC_James team. https://t.co/lEzzRjdcFc
-
-
Mashup Score: 1Defining and Measuring Financial Toxicity in Low- and Middle-Income Countries | JCO Oncology Practice - 2 hour(s) ago
PURPOSEFinancial toxicity (FT) of cancer treatment likely affects more patients in low- and middle-income countries (LMICs); however, most of the research on FT comes from high-income countries, which may not apply to LMICs. The causes and consequences of …This new article provides a comprehensive overview of how cancer treatment-related FT is defined across LMICs.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
However, if you look at studies on FT from LMICs, you’ll see that the definition is neither standardized nor tailored to the specific contexts. Everyone is defining FT whatever way they want. https://t.co/nfNskuLo8W
-
-
Mashup Score: 0Some Assembly Required - 2 hour(s) ago
The IKEA effect and my new carOnce upon a time, when you bought a car, all you needed to know was where the gear shift was, the parking brake, maybe the clutch, and how to start and stop the vehicle. Simple.Maybe the radio had a more sophisticated tuner, but the on/off knob was right where you’d expect. No fancy lights on the dashboard. No electronic screens. No voices directing us where to turn. No seat warmers. No blind spot monitors or lane changing jiggles.Start, Drive, apply brakes, stop, P
Source: www.askdoctored.comCategories: General Medicine News, Hem/OncsTweet-
For our 2025 car, the “owner's manual” was four books—one of which has 300 pages and twenty QR codes that take us to a downloadable website. Read the full article: Some Assembly Required ▸ https://t.co/khCedYl49k #newcartech #IKEA #RecentRoadTrip https://t.co/ljGmJhokaV
-
-
Mashup Score: 0McKee proposes $14B state budget that closes deficit with spending cuts, tax changes - 2 hour(s) ago
McKee wants a 10% tax on digital advertising, a $5-a-pack tax on cigarettes and new fees on electric vehicles, among other revenue ideas.
Source: www-wpri-com.cdn.ampproject.orgCategories: General Medicine News, Hem/OncsTweet-
McKee proposes $14B state budget that closes deficit with spending cuts, tax changes https://t.co/AHMXjycnrx
-
-
Mashup Score: 17Compara Carreras - 2 hour(s) ago
Te presentamos Compara Carreras, una herramienta gratuita diseñada para ayudarte a contrastar tus opciones de carrera y tomar decisiones informadas.
Source: comparacarreras.imco.org.mxCategories: General Medicine News, Hem/OncsTweet-
Carreras mejor pagadas en México 2024 ¿Estás de acuerdo? 👀 Referencia: https://t.co/zaAVkJpRbU https://t.co/h637Ix8ITo
-
-
Mashup Score: 10T-DXd Plus Pembrolizumab Elicits Responses in IO-Naive HER2-Expressing or -Mutant NSCLC - 3 hour(s) ago
Trastuzumab deruxtecan plus pembrolizumab showed early efficacy in patients with IO-naive, HER2-expressing or -mutant non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Hem/OncsTweet-
T-DXd Plus Pembrolizumab Elicits Responses in IO-Naive HER2-Expressing or -Mutant NSCLC https://t.co/SDzJOIPew8 via @onclive
-
-
Mashup Score: 2Toni's Legendary Top 10 Papers List! - 3 hour(s) ago
Dr Toni Choueiri, Chief of GU Oncology at Dana-barber Cancer Institute (Boston, USA) returns to GU Cast with members of his team at Dana Farber Cancer Instit…
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet-
We discussed @DrChoueiri 's 2024 #genitourinary #oncology Top10 articles along with my dear colleague @marc_eid hosted by @gu_onc ! (GUCast) Many thanks to @declangmurphy and @RenuEapen for this amazing speed-dating style discussion! https://t.co/MqLMzSfzk8 https://t.co/GBXUNxJjUV
-
-
Mashup Score: 4Impact of comorbidities on the mortality benefits of lung cancer screening: a post-hoc analysis of PLCO and NLST trials - 4 hour(s) ago
To evaluate how comorbidities affect mortality benefits of lung cancer screening (LCS) with low-dose computed-tomography (LDCT).
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet-
Interesting study shows PLCO-ci’ (co-morbidity) index improves pt selection for lung cancer screening @JTOonline - ⬇️LC mortality in pts with intermediate comorbidity (Q2-Q3-Q4) HR 0.62; 0,68; 0.72 - But not in pts with low/high PLCO-ci @OncoAlert #LCSM https://t.co/w17MyQ0Dxx
-
-
Mashup Score: 4FDA approves acalabrutinib with bendamustine and rituximab - 4 hour(s) ago
On January 16, 2025, the FDA granted traditional approval to acalabrutinib (Calquence, AstraZeneca) with bendamustine and rituximab for adults with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT).
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet-
FDA approves acalabrutinib with bendamustine and rituximab for previously untreated mantle cell lymphoma | FDA https://t.co/R2CvLQPian
-
Cancer’s New Face: Younger and Female https://t.co/9yHf7egoD6